Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is a Professor of Cancer Research and Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
…
continue reading

1
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
27:49
27:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요
27:49Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.
…
continue reading

1
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
43:59
43:59
나중에 재생
나중에 재생
리스트
좋아요
좋아요
43:59Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.
…
continue reading

1
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
45:46
45:46
나중에 재생
나중에 재생
리스트
좋아요
좋아요
45:46Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.
…
continue reading
ASCO2025の注目演題を取り上げ解説、ディスカッションしました!
…
continue reading
Brian, Tom and Silke discuss their highlights form ASCO 2025
…
continue reading

1
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
40:27
40:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요
40:27Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.
…
continue reading

1
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
37:22
37:22
나중에 재생
나중에 재생
리스트
좋아요
좋아요
37:22Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025
…
continue reading

1
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
19:39
19:39
나중에 재생
나중에 재생
리스트
좋아요
좋아요
19:39Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone
…
continue reading

1
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session
30:10
30:10
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:10Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
…
continue reading

1
Episode 423: ASCO 2025 - Casdatifan plus Cabo in refractory RCC
30:49
30:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:49Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
…
continue reading
Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.
…
continue reading

1
Episode 421: ASCO 2025 - Maintenance Avelumab +/- SG in Advanced Bladder Cancer
34:49
34:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요
34:49Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.
…
continue reading

1
Episode 420: ASCO 2025 - CheckMate 901: Ipi/Nivo vs chemo for Cis-ineligible metastatic urothelial cancer
24:18
24:18
나중에 재생
나중에 재생
리스트
좋아요
좋아요
24:18Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation
…
continue reading

1
Episode 419: ASCO 2025 - Correlate data from the IMmotion 010 RCC adjuvant study
23:49
23:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요
23:49Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.
…
continue reading
David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.
…
continue reading
Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。
…
continue reading
Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025
…
continue reading
日本と海外の違いはあるのか?mHSPCとmCRPCのUromigos Scoreについて激論!!
…
continue reading

1
Episode 414: Uromigos score en cáncer de próstata metastasico - más allá de las guías clínicas
28:23
28:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
28:23Edición especial en castellano con Alfonso Gómez de Liaño y Guillermo de Velasco. David Lorente da su visión sobre el nuevo Uromigos Score, que clasifica distintas opciones de tratamiento en varios escenarios de cáncer de próstata metastásico
…
continue reading

1
Episode 413: The Uromigos Score for Advanced Prostate Cancer
37:02
37:02
나중에 재생
나중에 재생
리스트
좋아요
좋아요
37:02Silke and Chris joins us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Several interesting themes emerge.
…
continue reading

1
Episode 410: AUA 2025 - BOND-003 Cohort C: Cretostimogene in BCG-Unresponsive NMIBC
28:52
28:52
나중에 재생
나중에 재생
리스트
좋아요
좋아요
28:52Mark Tyson from Mayo Clinic joins the podcast to discuss this replicating adenovirus and a high CR rate in BCG-unresponsive NMIBC
…
continue reading

1
Episode 412: AUA 2025 - TAR-200 Monotherapy in BCG-Unresponsive NMUIBC from SunRISe-1
37:20
37:20
나중에 재생
나중에 재생
리스트
좋아요
좋아요
37:20Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.
…
continue reading

1
Episode 411: Live from EIKCS in Amsterdam - RCC Highlights
20:26
20:26
나중에 재생
나중에 재생
리스트
좋아요
좋아요
20:26Viktor Grunwald joins to discuss the new data session from EIKCS
…
continue reading

1
Episode 409: AUA 2025 - CREST - BCG +/- Sasanlimab in high-risk NMIBC
47:27
47:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요
47:27Neal Shore joins the show to discuss these exciting data from the American Urological Association Annual Meeting
…
continue reading

1
Episode 408: Uromigos Japan - European Delphi Study of mRCCについてdiscussion
33:04
33:04
나중에 재생
나중에 재생
리스트
좋아요
좋아요
33:04今月Eur Urol OncolにPublishされたヨーロッパのエキスパートによるmRCCのコンセンサスについて日本との違いについて深い議論をしました!!
…
continue reading
Part 2 of our series dives deeper into the explosion of ADC clinical drug development in China
…
continue reading
Drs. Dingwei Ye and Yao Zhu from China join the show to talk about drug development in China amid the recent surge of GU clinical trials.
…
continue reading
Drs. Alicia Morgans and Chuck Ryan join the show to talk about their new podcast.
…
continue reading

1
Episode 404: 177 Lu-PSMA Pre-chemotherapy in mCRPC. Final Podcast from the Canary Islands
27:09
27:09
나중에 재생
나중에 재생
리스트
좋아요
좋아요
27:09Elena Castro joins Tom and Brian on the day after Pluvicto approval pre-chemotherapy in the US to discuss the PSMA Fore data and application in clinical practice.
…
continue reading

1
Episode 403: ADCs in Bladder Cancer. Part 2 from the Canary Islands
37:41
37:41
나중에 재생
나중에 재생
리스트
좋아요
좋아요
37:41Ignacio Duran continues his discussion with Brian and Tom regarding novel ADCS in bladder cancer
…
continue reading

1
Episode 402: Uromigos en Espanol: Futuro del carcinoma de células renales
25:12
25:12
나중에 재생
나중에 재생
리스트
좋아요
좋아요
25:12Cristina Suárez analiza los próximos ensayos clínicos que podrían transformar el manejo del cáncer renal en los próximos años: nuevas combinaciones adyuvantes y estrategias perioperatorias, el uso de tripletes enprimera línea y la integración de inhibidores de HIF con TKIs, entre otros.
…
continue reading

1
Episode 401: ADCs in Bladder Cancer. Part 1 from the Canary Islands
30:29
30:29
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:29Ignacio Duran joins the show to discuss the landscape of established ADCs in urothelial cancer and challenges of drug development in this setting.
…
continue reading
Live from the Canary Islands 'Big Idea' talk from Tom, we discuss the new Uromigos Score which ranks different treatment options in several urothelial cancer settings.
…
continue reading

1
Episode 399: A PD1/VEGF Bispecific in Lung Cancer - Lessons for GU Cancers?
36:44
36:44
나중에 재생
나중에 재생
리스트
좋아요
좋아요
36:44Dr. John Heymach from MD Andersons joins us to discuss a novel PD1/VEGF bispecific agent in lung cancer and if there are applicaitons in GU malignancies.
…
continue reading

1
Episode 398: Reflections on the Felix Feng Symposium at ASCO GU
32:05
32:05
나중에 재생
나중에 재생
리스트
좋아요
좋아요
32:05Chuck Ryan joins us to discuss his interview with Felix and reflects on his keynote address at ASCO GU 2025.
…
continue reading
Silke Gillessen joins us to discuss the top areas of consensus and controversy from APCCC 2025
…
continue reading
尿路上皮癌と腎癌の臨床に影響を与えるエビデンスをどう解釈するか!?
…
continue reading
ASCOGU2025で発表された臨床試験の結果の解釈について忖度なしに議論しました!!
…
continue reading

1
Episode 394: APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
30:27
30:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:27Tyler Seibert from UCSD joins the show live from Lugano to discuss meeting highlights and controversies (and his favorite run along the water..)
…
continue reading
Silke joins Tom and Brian to discuss highlights form ASCO GU 2025
…
continue reading

1
Episode 392: ASCO GU 2025 - HIF Inhibition with Casdatifan in Refractory RCC
30:09
30:09
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:09Toni Choueiri discusses the updated data from different cohorts of this novel HIF inhibitor.
…
continue reading

1
Episode 391: ASCO GU 2025 - KIM-1 Data from Checkmate 214
23:28
23:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
23:28Vincent Xu discusses this emerging RCC biomarker and data from the Checkmate 214 trial
…
continue reading

1
Episode 390: ASCO GU 2025 - Pembro-based Doublets in Refractory RCC and COSMIC-313 OS Update
30:03
30:03
나중에 재생
나중에 재생
리스트
좋아요
좋아요
30:03Laurence Albiges joins the show to discuss novel combos in refractory RCC and an update of the Ipi/Nivo/Cabo COSMIC OS data
…
continue reading

1
Episode 388: ASCO GU 2025 - FGF3 Inhibition with LOXO-435 in Urothelial Cancer
25:28
25:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
25:28Gopa Iyer from MSKCC joins the show to discuss his initial results from this phase 2 trial.
…
continue reading

1
Episode 387: ASCO GU 2025 -Neoadjuvant Disitamab Vedotin + Toripalimab in HER2+ MIBC: updated efficacy and safety results
27:07
27:07
나중에 재생
나중에 재생
리스트
좋아요
좋아요
27:07Xinan Sheng. M.D., Professor in the Department of Genitourinary Oncology at Peking University Cancer Hospital &institute in Beijing, China joins us to discuss the update of this trial and impressive pCR rates.
…
continue reading

1
Episode 389: ASCO GU 2025 - NIAGARA Pathologic CR Updates and Outcomes
28:23
28:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
28:23Matt Galsky joins the show to discuss pCR in NIAGARA and clinical implications.
…
continue reading
Tanya Dorff from City of Hope joins us to discuss clinical implications of these data and also comment on TALAPRO-2
…
continue reading
Neeraj Aggarwal joins Tom and Brian for an in-depth look at these important data
…
continue reading
Silke Gillessen joins Brian and Tom and they discuss what to look forward to in prostate, bladder and RCC at ASCO GU 2025.
…
continue reading

1
Episode 383: A Neoantigen Vaccine Generates Anti-tumor Immunity in RCC
33:11
33:11
나중에 재생
나중에 재생
리스트
좋아요
좋아요
33:11David Braun joins the show to discuss his Nature paper on a personalized RCC vaccine
…
continue reading